ClinicalTrials.gg
RecruitingNCT06378229PSIHOS-DUpdated Sep 19, 2024

Psilocybin for Hospitalized Patients with Treatment-resistant Depression

A Phase 2 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University Hospital, Ghent · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.

Planned enrollment
6th of 25
100 · median 30
Started
2024
with 5 others
Phase 2
18 of 25
8 open now
Primary completion
2026-03
later than 3 of 13 live
Registered
16th of 25
by date

Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 6th largest by planned enrollment, is one of 6 that started in 2024, is one of 18 in phase 2, reaches primary completion later than 3 of the 13 other live ones, and was the 16th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression.

Read the detailed description

The proposed study will assess the safety, feasibility, preliminary results and neurological aspects of psilocybin-assisted psychotherapy in the treatment of hospitalized patients with treatment-resistant depression.

Screening, after signing the ICF, is done in patients newly admitted to the psychiatric service of Ghent University Hospital or patients referred for hospitalization through the outpatient clinic of the psychiatric service of Ghent University Hospital. Involved patients are hospitalized at the Anxiety, Compulsion and Mood Unit for 8 weeks. They will receive add-on treatment with psilocybin-supported psychotherapy in addition to standard treatment (daily group therapies, mainly non-verbal and activating). This consists of a preparatory phase (4 sessions of 1.5 hours before the first psilocybin session and 1 session of 1.5 hours before the second psilocybin session), the psilocybin sessions themselves (2 sessions, week 3 and week 6) and an integration phase (3 sessions of 1.5 hours after each psilocybin session). All sessions occur with the same 2 therapists throughout the entire course. Therapists are trained to provide experiential and systemic psychotherapeutic interventions.

After hospitalization, weekly outpatient follow-up consultations continue until 12 weeks after the last psilocybin session. Subsequently, patients may still agree to a prospective, observational and naturalistic follow-up until 1 year after the last psilocybin session, during which they will be called monthly by a psychiatrist from the research team to inquire about current mental status and any therapies undertaken in the interim.

During the study, patients are required to fill out questionnaires at regular intervals. Video-recordings will be made of certain parts of the preparation and integration sessions, for analysis with the client experience scale (EXP). The morning of each psilocybin session, female patients must provide a blood sample for a pregnancy test. The morning of each psilocybin session, all patients must provide a urine sample for toxicology screening. EEGs are also taken from patients the day before each psilocybin session, the morning of the first integration session after each psilocybin session and 12 weeks after the last psilocybin session (at the last outpatient consultation). At the start and at the end of the hospitalization phase, a semi-structured interview will be conducted with the patient to gauge expectations on the one hand and experiences on the other.

Throughout the study, the patient's partner will be involved. The partner must complete a number of questionnaires at baseline and throughout the study and will have to be present at 3 EEGs. In addition, the partner will also participate in 1 preparatory session and 2 integration sessions. The partner will also be given the opportunity to spend the night of a psilocybin session with the patient in the hospital (rooming-in). At the start and at the end of the hospitalization phase, a semi-structured interview will be conducted with the partner to gauge expectations on the one hand and experiences on the other.

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Diagnosis of major depressive disorder (single and recurrent episodes) of moderate to severe degree (MADRS score ≥ 20) according to the (DSM-5), without psychotic features. Included ICD-11 diagnoses are ICD-11: 6A70.1, 6A70.3, 6A71.1, 6A71.3.
  3. Subjects have failed to respond to 2 or more antidepressants prescribed at the minimum effective dose for at least 6 weeks. Augmentation with an add-on treatment counts as a second treatment.
  4. The subjects are abstinent from alcohol (breathalyzer blood alcohol concentration (BAC) level 0.00) and provide a negative urine drug screen at the dosing day.
  5. The female subjects provide a negative pregnancy test at the dosing day.
  6. The subjects must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead performed at screening.

    • In 12-lead ECG, should be ≤ 450 ms for males or ≤ 470 ms for females and PR-interval \< 220 ms at screening.
  7. A partner is willing to participate in the study (a cohabiting relationship of at least 1 year).

Exclusion criteria

Exclusion Criteria:

  1. Currently comorbid or previously diagnosed diagnosis of a

    1. major depressive episode with psychotic features.
    2. psychotic disorder (defined as meeting DSM-5 criteria for any psychotic disorder) on the MINI 7.0, EXCEPT substance/medication induced psychotic disorder where the duration was limited to the acute period of direct intoxication with the substance/medication. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
    3. bipolar disorder (defined as meeting DSM-5 criteria for bipolar type 1 or bipolar type 2) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
    4. drug or alcohol dependence syndrome (defined as meeting DSM-5 criteria for any dependence syndrome) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
    5. cluster B personality disorder. Subjects will be screened for the presence of those personality traits by using the NEO-FFI-3.
    6. PTSD (defined as meeting DSM-5 criteria for PTSD) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
  2. A family history (first-degree relative) of psychosis and/or bipolar disorder.
  3. Current active suicidal ideations.
  4. Depression secondary to other medical conditions.
  5. Medical diagnosis incompatible with psilocybin treatment:

    1. Cardiovascular conditions: recent stroke (\< 1 year from signing of ICF), recent myocardial infarction (\< 1 year from signing of ICF), uncontrolled hypertension (blood pressure > 140/90 mmHg) or arrhythmia within 1 year of signing the ICF.
    2. Uncontrolled insulin-dependent diabetes mellitus.
    3. Uncontrolled epilepsy.
  6. Biochemical or electrocardiographic abnormalities determined as clinically significant by a medical doctor. PsiHos-D, Version 2.1 dd. 22/02/2024 page 59 of 114 TMP_Protocol AGO CTR_Version 1.0_Effective Date 2022-07-18
  7. Current intake of Lithium, Disulfiram, MAOIs or inhibitors of UGT1A9 and 1A10.
  8. The subject has received any prior treatment with vagal nerve stimulation, or a deep brain stimulation device.
  9. Women of not using adequate (methods that can achieve a failure rate of less than 1%: combined hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence). A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
  10. Pregnant or breast-feeding women.
  11. Those unable to give .
  12. Those enrolled in another trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Open label: full dose Psilocybin

    2 doses of 25mg Psilocybin, 3 weeks apart (week 3 and week 6), accompanied by 7,5 hours of preparation sessions and 9 hours of integration sessions.

    Drug: Psilocybin

Interventions

  • A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).

    Also known as: PEX010

06

What researchers measure

Primary outcomes

  1. Incidence and type of Treatment-Emergent Adverse Events

    The safety of performing psilocybin-assisted psychotherapy in treatment-resistant depression (TRD) in a hospitalized setting. Adverse Events (AEs) will be classified by the clinical team based on severity, whether they are expected or unexpected and causality.

    Time frame: 18 weeks

  2. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Clinician-administered measure of suicidal ideation. Scores range from 0 to 25, with higher scores indicating more severe suicidal ideation.

    Time frame: 18 weeks

Secondary outcomes

  1. Recruitment and retention rates.

    The feasibility of performing psilocybin-assisted psychotherapy in TRD in a hospitalized setting.

    Time frame: 8 weeks (end of hospitalization).

  2. Qualitative data from the semi-structured interviews with the subjects and their partners.

    Acceptability of the intervention and procedures for the subjects as assessed through semi-structured interviews.

    Time frame: 8 weeks (end of hospitalization).

Other outcomes

  1. Montgomery Asberg Depression Rating Scale (MADRS)

    A ten-item clinician-rated diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Scoring ranging from 0 to 60, with higher scores indicating greater depressive symptomology.

    Time frame: 18 weeks (optional up to 58 weeks).

  2. Quick Inventory of Depressive Symptomatology - Self Rated (QIDS-SR)

    A self report measure of depressive symptoms. Scores range from 0 to 27, with lower scores indicating less symptoms of depression.

    Time frame: 18 weeks.

  3. State-Trait Anxiety Inventory (STAI)

    A self report measure of anxiety symptoms. Scores range from 20 to 80, with higher scores correlating with greater anxiety.

    Time frame: 18 weeks.

  4. World Health Organization Quality of Life Inventory-Brief subscale (WHOQOL-BREF)

    A self-report measure of quality of life with four subscales: Physical Health, Psychological Health, Social Relationships, and Environment. Scores for each range from 4-20, with higher scores indicating better quality of life.

    Time frame: 18 weeks (optional up to 58 weeks).

  5. Maudsley 3-item Visual Analogue Scale (M3VAS)

    A self report measure of depressive symptoms using 3 visual analogue scales. Scores range from 0 to 300, with lower scores indicating less symptoms of depression.

    Time frame: 18 weeks.

  6. Subjective Emotional Health Visual Analogue Scale (SEHVAS)

    Visual Analogue Scale rating the emotional health of the subject as perceived by the partner. Scores range from 0 to 100, with higher scores indicating a better emotional health.

    Time frame: 18 weeks.

  7. revised Dyadic Adjustment Scale (RDAS)

    A 14-item questionnaire that measures an individual's perceptions of his/her relationship with an intimate partner. Scores range from 0-69, with higher scores indicating higher consensus, satisfaction and cohesion.

    Time frame: 18 weeks (optional up to 58 weeks).

  8. Zarit Burden Interview - Short Form (Zarit-12 Burden Scale)

    A self-administered 12-item questionnaire that measures the burden of taking care for a close relative. Scores range from 0 to 48, with higher scores indicating a greater burden of care.

    Time frame: 18 weeks.

  9. Client Experiencing Scale (EXP)

    A 7-item scale assessing the experiential level of the subject. Higher stages indicate higher levels of experiencing.

    Time frame: Week 2, 3, 5 and 6.

  10. Mystical Experience Questionnaire (MEQ)

    A 30-item questionnaire that measures the mystical quality of an experience. Scores range from 0 to 5, with higher scores indicating a greater mystical quality of the experience.

    Time frame: Within 24 hours after each psilocybin session (week 3 and week 6).

  11. Working Alliance Inventory - Short Revised (WAI-SR)

    A 12-item questionnaire that measures the quality of the therapeutic relationship. Scores range from 1 to 5, with higher scores indicating better quality of the therapeutic relationship.

    Time frame: 8 weeks.

  12. Semi-structured interviews.

    Semi-structured interviews with both subjects and their partners, assessing their expectations and experiences.

    Time frame: Week 1 and week 8.

  13. EEG: sensor level analysis (power) and source level analysis (functional connectivity through amplitude envelope correlation), both in resting state and during an emotional paradigm.

    A method aimed at examining intrinsic networks in the brain to estimate correlations between brain regions.

    Time frame: Week 3, week 6, week 18.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2026, 22 months after the start.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Apr 22, 2024
StartActual
May 21, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06378229
Collaborators
Filament Health Corp.
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
May 21, 2024
Primary completion
Mar 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Cisse Geleyn, dr.
Contact
cisse.geleyn@uzgent.be
003293328742
Gilbert Lemmens, Prof. dr.
principal investigator · University Hospital, Ghent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion